News

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

DENVER, April 30, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions…

2 years ago

BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts

POMPANO BEACH, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused…

2 years ago

STRATA Skin Sciences Announces XTRAC® Comeback Placements in the First Quarter of 2024

HORSHAM, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical…

2 years ago

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

– Preclinical data demonstrates the potential for improved treatment outcomes and reduced toxicity for patients with AML – – Data…

2 years ago

Noom Establishes Its First-Ever Social Impact Program with the Launch of Noom Impact, Providing Free Health Solutions to People in Need

In its first initiative Noom partners with Project Donor, helping organ donor candidates become eligible to save lives NEW YORK,…

2 years ago

Goodness Growth Holdings to Release First Quarter 2024 Results on May 7, 2024

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF),…

2 years ago

Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and…

2 years ago

Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005

– A-005 is a potential first-in-class, CNS penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – –…

2 years ago

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through…

2 years ago

Inspire Medical Systems, Inc. to Present at the BofA Securities 2024 Health Care Conference

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on…

2 years ago